Results 181 to 190 of about 41,379 (243)

Characterization of anti-fentanyl antibodies as antagonists of ultra-toxic, clinically relevant or endogenous opioids. [PDF]

Arch Toxicol
Endt F, Steinritz D, Amend N, Gudermann T, Breit A.   +4 more
europepmc   +1 more source

Recruiting a National Sample of First Response Agencies to Participate in an Overdose Prevention Research Project: Randomized Controlled Trial and Feasibility Study. [PDF]

JMIR Form Res
Agley J, Henderson C, Nair M, Seo DC, Parker M, Golzarri-Arroyo L, Dickinson S, Tidd D.   +7 more
europepmc   +1 more source

Collaboration with community partners to expand naloxone access in the HEALing Communities Study. [PDF]

J Am Pharm Assoc (2003)
Ingram T, Rubi S, Dantzler S, DeFiore-Hyrmer J, Brown JL, Sprunger J, Winhusen TJ, Lyons MS.   +7 more
europepmc   +1 more source

Survey of local patterns of fentanyl exposure and harm reduction strategies in the Southeastern United States. [PDF]

Ment Health Clin
Tenn KE, Robert S, Mosley B, Rarrick C.
europepmc   +1 more source

Reserpine-induced fibromyalgia model in female rats is a long-lasting painful condition masked by antinociceptive endogenous opioids. [PDF]

Front Pharmacol
Juárez-Núñez C, Segura-Chama P, Pizaña-Encarnación JM, Pellicer F, Granados-Soto V, Mercado F, Almanza A.   +6 more
europepmc   +1 more source

"Smart" harm reduction vending machines to improve public health: Evaluating the utilization. [PDF]

J Subst Use Addict Treat
Zhang A, Murphy J, Griffin PM, Goodman-Hinnershitz M, Pinto CN, Ballard SM, Grigson PS, Kawasaki SS, Tuan WJ, Zgierska AE.   +9 more
europepmc   +1 more source

Effect of Ultra-low-dose Naloxone on Ileus after Cesarean Section: A Randomized Clinical Trial. [PDF]

J Res Pharm Pract
Baradari AG, Hadian A, Boskabadi SJ, Sohrabi M, Heydari F, Alipour A, Emadi SA.   +6 more
europepmc   +1 more source

Take home naloxone reports.

core